Loading clinical trials...
Loading clinical trials...
A Phase III Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of Odanacatib (MK-0822) to Reduce the Risk of Fracture in Osteoporotic Postmenopausal Women Treated With Vitamin D and Calcium
Conditions
Interventions
Odanacatib
Placebo for Odanacatib
+2 more
Start Date
September 13, 2007
Primary Completion Date
November 14, 2012
Completion Date
February 1, 2017
Last Updated
June 11, 2024
NCT06767150
NCT05902078
NCT05010590
NCT02822378
NCT07329543
NCT06079476
Lead Sponsor
Merck Sharp & Dohme LLC
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions